RxDoctor Payments DataLook up a doctor →

Martha McGraw, MD

Neurology · Winfield, ILNPI 1437101615

Payments from drug & device makers

$1,032,212in general payments, 2019–2025

Across 663 payments — averaging $1556.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$264K
  • Acadia Pharmaceuticals Inc$192K
  • Teva Pharmaceuticals USA, Inc.$175K
  • Amneal Pharmaceuticals LLC$149K
  • MDD US Operations, LLC$130K
  • H. Lundbeck A S$45K
  • plus $78K from 8 others

What the payments were for

  • Consulting fees$36,7646%
  • Speaking & faculty fees$523,88584%
  • Travel & lodging$45,9647%
  • Food & beverage$16,9293%
  • Education$1,7450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,032,212 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$218,357
Medicare patients
260
Services billed
16,750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate129$707,844
GocovriAmantadine Hcl162$620,808
RytaryCarbidopa/Levodopa403$542,530
Austedo XrDeutetrabenazine42$373,253
Droxidopa91$165,610
AustedoDeutetrabenazine26$132,482
NeuproRotigotine61$105,992
XadagoSafinamide Mesylate40$100,866
Rasagiline Mesylate167$42,638
Rivastigmine129$32,454
Carbidopa-LevodopaCarbidopa/Levodopa669$27,657
Carbidopa-Levodopa ErCarbidopa/Levodopa418$15,131
AmantadineAmantadine Hcl119$8,689
Tetrabenazine29$4,908
Ropinirole ErRopinirole Hcl27$4,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$191,668$707,844129 claims
MDD US Operations, LLCGocovri$130,216$620,808162 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$148,932$543,447430 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$174,510$505,73568 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.

Other neurology in Winfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →